Medical Advances in Pancreas Transplantation
Transplant Immunology Research
Emory is at the forefront of research into new immunosuppressant therapies. Our physicians are investigating new drugs that can establish true immune tolerance with fewer toxic side effects (high blood pressure, high cholesterol, kidney damage) than traditional immunosuppressants.
Recent clinical trials at Emory have offered exciting results. An experimental drug called belatacept can better preserve kidney function in kidney transplant recipients while preventing rejection when compared with the standard drug cyclosporine. This is the first time a new class of drugs has been developed for transplant since the 1980s, says Emory Transplant Center Director Christian Larsen, MD. Belatacept has the potential to improve and simplify the medication regimens of transplant recipients, not only for kidney transplant but potentially other types of organ transplants as well.
VIDEO: Dr. Christian Larsen discusses the experimental anti-rejection drug Belatacept
Living Donation
Emory is one of just a few centers around the country offering living donor kidney-pancreas transplantation. In living donor transplantation, the donor (usually a family member or friend) donates a kidney and a portion of their pancreas. Not only does living donation shorten the wait time for organs for often critically ill patients, but it also has excellent outcomes and can create a strong bond between donor and recipient.
